Mirae Asset Global Investments Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,079 shares of the company’s stock, valued at approximately $80,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. raised its stake in NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after buying an additional 628,251 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of NewAmsterdam Pharma by 291.9% in the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock worth $102,763,000 after buying an additional 2,978,263 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock valued at $25,607,000 after buying an additional 520,772 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its position in shares of NewAmsterdam Pharma by 19.5% during the third quarter. ArrowMark Colorado Holdings LLC now owns 354,975 shares of the company’s stock valued at $5,893,000 after acquiring an additional 57,806 shares in the last quarter. Finally, FMR LLC lifted its position in NewAmsterdam Pharma by 35.6% in the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock valued at $5,485,000 after acquiring an additional 86,712 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $19.91 on Friday. The stock’s 50-day simple moving average is $23.64 and its two-hundred day simple moving average is $20.09. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

Insider Activity at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the transaction, the insider now directly owns 11,778,760 shares of the company’s stock, valued at approximately $295,411,300.80. This trade represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 438,200 shares of company stock worth $11,225,274. 19.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on NAMS shares. HC Wainwright restated a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Royal Bank of Canada restated an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Buy” and an average price target of $41.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.